The impact of molecular targets in cancer drug development: major hurdles and future strategies - PubMed

The impact of molecular targets in cancer drug development: major hurdles and future strategies

Alexandra Hebar et al. Expert Rev Clin Pharmacol. 2013 Jan.

Abstract

The last decades were characterized by enormous technological advances resulting in a better understanding of disease pathologies and improvement of treatment strategies. The development of targeted drugs, whose beginning can be traced back to Paul Ehrlich's theory of the 'magic bullet' approximately 100 years ago, is today widely appraised as a promising strategy to combat benign, as well as malignant, diseases. Over 40 years after US President Nixon declared the 'war on cancer', treatment outcome, especially of solid tumors in the advanced stages of disease, still lies far behind expectations. In this perspective article, the authors discuss the recent development of targeted cancer drugs and identify major hurdles. The authors further highlight future strategies that might improve and accelerate the drug-development process.

Similar articles

• [Development of antituberculous drugs: current status and future prospects].

  Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.

• A history of cancer chemotherapy.

  DeVita VT Jr, Chu E. DeVita VT Jr, et al. Cancer Res. 2008 Nov 1;68(21):8643-53. doi: 10.1158/0008-5472.CAN-07-6611. Cancer Res. 2008. PMID: 18974103

• Paul Ehrlich's magic bullet concept: 100 years of progress.

  Strebhardt K, Ullrich A. Strebhardt K, et al. Nat Rev Cancer. 2008 Jun;8(6):473-80. doi: 10.1038/nrc2394. Epub 2008 May 12. Nat Rev Cancer. 2008. PMID: 18469827 Review.

• [The development history and future perspective of molecularly targeted therapy].

  Mizuki M, Kanakura Y. Mizuki M, et al. Nihon Rinsho. 2014 Jun;72(6):997-1003. Nihon Rinsho. 2014. PMID: 25016795 Review. Japanese.

• The convergence of cancer prevention and therapy in early-phase clinical drug development.

  Abbruzzese JL, Lippman SM. Abbruzzese JL, et al. Cancer Cell. 2004 Oct;6(4):321-6. doi: 10.1016/j.ccr.2004.09.021. Cancer Cell. 2004. PMID: 15488755 Review.

Cited by

• How aging of the global population is changing oncology.

  Gu YF, Lin FP, Epstein RJ. Gu YF, et al. Ecancermedicalscience. 2021 Dec 13;15:ed119. doi: 10.3332/ecancer.2021.ed119. eCollection 2021. Ecancermedicalscience. 2021. PMID: 35211208 Free PMC article.

• In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment.

  Ciftci H, Sever B, Ocak F, Bayrak N, Yıldız M, Yıldırım H, DeMirci H, Tateishi H, Otsuka M, Fujita M, TuYuN AF. Ciftci H, et al. Molecules. 2022 Jan 21;27(3):693. doi: 10.3390/molecules27030693. Molecules. 2022. PMID: 35163957 Free PMC article.

• Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling.

  Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. Agren R, et al. Mol Syst Biol. 2014 Mar 19;10(3):721. doi: 10.1002/msb.145122. Mol Syst Biol. 2014. PMID: 24646661 Free PMC article.

• The quinone-based derivative, HMNQ induces apoptotic and autophagic cell death by modulating reactive oxygen species in cancer cells.

  Lee EB, Cheon MG, Cui J, Lee YJ, Seo EK, Jang HH. Lee EB, et al. Oncotarget. 2017 Sep 18;8(59):99637-99648. doi: 10.18632/oncotarget.21005. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245930 Free PMC article.

• Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling.

  Ghaffari P, Mardinoglu A, Asplund A, Shoaie S, Kampf C, Uhlen M, Nielsen J. Ghaffari P, et al. Sci Rep. 2015 Feb 2;5:8183. doi: 10.1038/srep08183. Sci Rep. 2015. PMID: 25640694 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations